Targeted disruption of the gene encoding the murine small subunit of carboxypeptidase N (CPN1) causes susceptibility to C5a anaphylatoxin-mediated shock

Journal of Immunology

Volumn 182, Issue 10, 2009, Pages 6533-6539

  Mueller Ortiz, Stacey L ^a   Wang, Dachun ^a   Morales, John E ^a   Li, Li ^a   Chang, Jui Yoa ^a   Wetsel, Rick A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ARGININE CARBOXYPEPTIDASE; COBROTOXIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; HISTAMINE;

ANAPHYLACTIC SHOCK; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; FEMALE; GENE DISRUPTION; GENE TARGETING; GENETIC CODE; HISTAMINE RELEASE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SWINE;

ANIMALS; BLOTTING, SOUTHERN; COBRA VENOMS; COMPLEMENT C3A; COMPLEMENT C5A; COMPLEMENT INACTIVATING AGENTS; DISEASE SUSCEPTIBILITY; FEMALE; HISTAMINE; HUMANS; LYSINE CARBOXYPEPTIDASE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SHOCK;

EID: 70349465190     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0804207     Document Type: Article

References (46)

1. Matthews, K. W., S. L. Mueller-Ortiz, and R. A. Wetsel. 2004. Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol. Immunol. 40: 785-793.
2. Skidgel, R. A. 1996. Structure and function of mammalian zinc carboxypeptidase. In Zinc Metalloprotease in Health and Disease. N. M. Hooper, ed. Taylor and Francis, London, pp. 241-283.
3. Skidgel, R. A., and E. G. Erdos. 2007. Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator. Int. Immunopharmacol. 7: 1888-1899.
4. Levin, Y., R. A. Skidgel, and E. G. Erdos. 1982. Isolation and characterization of the subunits of human plasma carboxypeptidase N (kininase i). Proc. Natl. Acad. Sci. USA 79: 4618-4622.
5. Erdos, E. G., and E. M. Sloane. 1962. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 11: 585-592.
6. Bokisch, V. A., and H. J. Muller-Eberhard. 1970. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49: 2427-2436.
7. Wetsel, R. A., J. Kildsgaard, and D. L. Haviland. 2000. Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation. In Contemporary Immunology: Therapeutic Interventions in the Complement System. J. D. Lambris and V. M. Holers, eds. Humana, Totowa, NJ, pp. 113-154.
8. Davis, D. A., K. E. Singer, M. De La Luz Sierra, M. Narazaki, F. Yang, H. M. Fales, R. Yarchoan, and G. Tosato. 2005. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1α in the circulation. Blood 105: 4561-4568.
9. De La Luz Sierra, M., F. Yang, M. Narazaki, O. Salvucci, D. Davis, R. Yarchoan, H. H. Zhang, H. Fales, and G. Tosato. 2004. Differential processing of stromalderived factor-1α and stromal-derived factor-1β explains functional diversity. Blood 103: 2452-2459. (Pubitemid 38392993)
10. Mathews, K. P., P. M. Pan, N. J. Gardner, and T. E. Hugli. 1980. Familial carboxypeptidase N deficiency. Ann. Intern. Med. 93: 443-445.
11. Mathews, K. P., J. G. Curd, and T. E. Hugli. 1986. Decreased synthesis of serum carboxypeptidase N (SCPN) in familial SCPN deficiency. J. Clin. Immunol. 6: 87-91.
12. Cao, H., and R. A. Hegele. 2003. DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency. J. Hum. Genet. 48: 20-22. (Pubitemid 36205642)
13. Willemse, J. L., D. Chen, and D. F. Hendriks. 2008. Major carboxypeptidase N deficiency. Clin. Chim. Acta 389: 181-182.
14. Matthews, K. W., S. M. Drouin, C. Liu, J. F. Martin, R. A. Skidgel, and R. A. Wetsel. 2004. Expression of the third complement component (C3) and carboxypeptidase N small subunit (CPN1) during mouse embryonic development. Dev. Comp. Immunol. 28: 647-655.
15. Matthews, K. W., and R. A. Wetsel. 2001. Characterization of mouse carboxypeptidase N small active subunit gene structure. J. Immunol. 166: 6196-6202. (Pubitemid 32440750)
16. Campbell, W. D., E. Lazoura, N. Okada, and H. Okada. 2002. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol. Immunol. 46: 131-134.
17. Skidgel, R. A. 1995. Human carboxypeptidase N: lysine carboxypeptidase. Methods Enzymol. 248: 653-663.
18. Kildsgaard, J., T. J. Hollmann, K. W. Matthews, K. Bian, F. Murad, and R. A. Wetsel. 2000. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxinshock. J. Immunol. 165: 5406-5409.
19. Hollmann, T. J., S. L. Mueller-Ortiz, M. C. Braun, and R. A. Wetsel. 2008. Disruption of the C5a receptor gene increases resistance to acute Gram-negative bacteremia and endotoxic shock: opposing roles of C3a and C5a. Mol. Immunol. 45: 1907-1915.
20. Dillard, P., R. A. Wetsel, and S. M. Drouin. 2007. Complement C3a regulates Muc5ac expression by airway Clara cells independently of Th2 responses. Am. J. Respir. Crit. Care Med. 175: 1250-1258. (Pubitemid 46905750)
21. Plummer, T. H., Jr., and M. T. Kimmel. 1980. An improved spectrophotometric assay for human plasma carboxypeptidase N1. Anal. Biochem. 108: 348-353. (Pubitemid 11182101)
22. Oshima, G., J. Kato, and E. G. Erdos. 1975. Plasma carboxypeptidase N, subunits and characteristics. Arch. Biochem. Biophys. 170: 132-138.
23. McKay, T. J., A. W. Phelan, and T. H. Plummer, Jr. 1979. Comparative studies on human carboxypeptidases B and N. Arch. Biochem. Biophys. 197: 487-492.
24. Vogel, C. W., R. Bredehorst, D. C. Fritzinger, T. Grunwald, P. Ziegelmuller, and M. A. Kock. 1996. Structure and function of cobra venom factor, the complement-activating protein in cobra venom. Adv. Exp. Med. Biol. 391: 97-114.
25. Boeckler, P., A. Meyer, B. Uring-Lambert, J. Goetz, B. Cribier, G. Hauptmann, and D. Lipsker. 2006. Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus?: a study of 25 patients. Clin. Immunol. 121: 198-202. (Pubitemid 44572978)
26. Pfarr, N., D. Prawitt, M. Kirschfink, C. Schroff, M. Knuf, P. Habermehl, W. Mannhardt, F. Zepp, W. Fairbrother, M. Loos, et al. 2005. Linking C5 deficiency to an exonic splicing enhancer mutation. J. Immunol. 174: 4172-4177. (Pubitemid 40395995)
27. Hugli, T. E., and H. J. Muller-Eberhard. 1978. Anaphylatoxins: C3a and C5a. Adv. Immunol. 26: 1-53.
28. Suckow, M. A., P. Danneman, and C. Brayton. 2001. Experimental methodology. In The Laboratory Mouse. CRC, Boca Raton, FL, pp. 113-134.
29. Gressner, O., U. Meier, S. Hillebrandt, H. E. Wasmuth, J. Kohl, T. Sauerbruch, and F. Lammert. 2007. Gc-globulin concentrations and C5 haplotype-tagging polymorphisms contribute to variations in serum activity of complement factor C5. Clin. Biochem. 40: 771-775. (Pubitemid 46961957)
30. Ogawa, Y., and J. A. Grant. 2007. Mediators of anaphylaxis. Immunol. Allergy Clin. North Am. 27: 249-260, vii.
31. Bajzar, L., J. Morser, and M. Nesheim. 1996. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 271: 16603-16608. (Pubitemid 26239017)
32. Eaton, D. L., B. E. Malloy, S. P. Tsai, W. Henzel, and D. Drayna. 1991. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 266: 21833-21838.
33. Tan, A. K., and D. L. Eaton. 1995. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 34: 5811-5816.
34. Kawamura, T., N. Okada, and H. Okada. 2002. Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol. Immunol. 46: 225-230. (Pubitemid 34289020)
35. Asai, S., T. Sato, T. Tada, T. Miyamoto, N. Kimbara, N. Motoyama, H. Okada, and N. Okada. 2004. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J. Immunol. 173: 4669-4674. (Pubitemid 39280701)
36. Nagashima, M., Z. F. Yin, L. Zhao, K. White, Y. Zhu, N. Lasky, M. Halks-Miller, G. J. Broze, Jr., W. P. Fay, and J. Morser. 2002. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J. Clin. Invest. 109: 101-110. (Pubitemid 34052546)
37. Swaisgood, C. M., D. Schmitt, D. Eaton, and E. F. Plow. 2002. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J. Clin. Invest. 110: 1275-1282.
38. te Velde, E. A., G. T. Wagenaar, A. Reijerkerk, M. Roose-Girma, I. H. Borel Rinkes, E. E. Voest, B. N. Bouma, M. F. Gebbink, and J. C. Meijers. 2003. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J. Thromb. Haemost. 1: 2087-2096.
39. Huey, R., C. M. Bloor, M. S. Kawahara, and T. E. Hugli. 1983. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN), I: Lethality and pathologic effects on pulmonary tissue. Am. J. Pathol. 112: 48-60. (Pubitemid 13069240)
40. Tvedten, H. W., G. O. Till, and P. A. Ward. 1985. Mediators of lung injury in mice following systemic activation of complement. Am. J. Pathol. 119: 92-100. (Pubitemid 15088728)
41. Mulligan, M. S., E. Schmid, B. Beck-Schimmer, G. O. Till, H. P. Friedl, R. B. Brauer, T. E. Hugli, M. Miyasaka, R. L. Warner, K. J. Johnson, and P. A. Ward. 1996. Requirement and role of C5a in acute lung inflammatory injury in rats. J. Clin. Invest. 98: 503-512. (Pubitemid 26255752)
42. Proctor, L. M., A. J. Strachan, T. M. Woodruff, I. B. Mahadevan, H. M. Williams, I. A. Shiels, and S. M. Taylor. 2006. Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. Int. Immunopharmacol. 6: 1224-1232.
43. Proctor, L. M., T. V. Arumugam, I. Shiels, R. C. Reid, D. P. Fairlie, and S. M. Taylor. 2004. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br. J. Pharmacol. 142: 756-764.
44. Mathieu, M. C., N. Sawyer, G. M. Greig, M. Hamel, S. Kargman, Y. Ducharme, C. K. Lau, R. W. Friesen, G. P. O'Neill, F. G. Gervais, and A. G. Therien. 2005. The C3a receptor antagonist SB 290157 has agonist activity. Immunol. Lett. 100: 139-145. (Pubitemid 41262011)
45. Takagi, K., and T. Fukao. 1971. Effects of some drugs on capillary permeability in the anaphylaxis of the mouse. Jpn. J. Pharmacol. 21: 455-465.
46. Henderson, J. D., and H. Smith. 1970. Turnover of pulmonary alveolar wall cells in guinea-pig and mouse after anaphylactic shock. Br. J. Pharmacol. 38: 442P-443P.